Noble launches its YpsoMate training device platform, elevates patient access

ORLANDO, Fla.–(BUSINESS WIRE)–Noble, the global leader in medical device training solutions, patient
onboarding strategies and multisensory product development for the
world’s top pharmaceutical brands, unveiled today a new injection
training platform based on 1 mL and 2.25 mL YpsoMate devices to help
improve patient onboarding and health outcomes.

Given that 49 percent of patients prescribed injection-based therapies
do not receive training in a healthcare providers’ office and 90 percent
of treatment information is forgotten in a week, it’s important for
brands to take a holistic approach to ensuring patients are familiar and
confident with using their device, understand their condition and
treatment plan and remain adherent to therapy. Noble’s training and
onboarding solutions accomplish just that by providing patients with an
assortment of educational support tools and materials to make up for any
treatment, learning and other gaps they may experience.

“As part of our commitment to improving the patient journey and ensuring
access to best-in-class, top-quality training devices, we’ve taken a
proactive approach to developing this new injection training platform,”
said Jeff Baker, CEO of Noble. “While the new platform looks exactly
like the real device, it is different in that it incorporates a host of
innovative core device features and capabilities developed to give
patients a hyper-realistic simulated injection experience.”

Noble’s convenient, forward-looking YpsoMate training platform – which
centers on a resettable, pre-tooled core device with a variety of
plunger speed options – benefits brands by delivering superior quality,
faster speed to market (including utilization in clinical trials and
commercial launch planning) and no capital tooling expense. Meanwhile,
users will benefit from having a comprehensive, engaging training and
onboarding system that provides HCPs with an in-office resource for
educating patients and offers patients an in-home solution for multi-use
practice sessions and interactive firsthand training on demand.

“Through research we’ve found patients with training devices were more
engaged and practiced more prior to an injection than those without a
trainer,” adds Baker. “With longer periods of time between
self-injections, giving patients the ability to have refreshers prior to
injecting will reinforce user confidence with correctly using a device.
We believe empowering patients to be more engaged with managing their
health will lead to improvements in adherence and health outcomes.”